Could a daily pill replace hormone shots for prostate cancer?

NCT ID NCT07299292

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether taking abiraterone 250 mg with food and prednisone can lower testosterone to castration levels in prostate cancer patients, without using standard hormone-blocking injections or surgery. The study enrolls 60 men with prostate cancer who need hormone therapy. If it works, it could offer a more convenient, all-oral treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abiraterone 250 mg with food plus prednisone
What this could lead to
If successful, this could offer a simpler, pill-only option to lower testosterone in prostate cancer patients, avoiding the need for injections or surgery.
What could go wrong
This is a small, early-phase trial with only 60 participants. It may not work as well as standard treatments, and abiraterone can cause side effects like high blood pressure or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Carlos A Durand

    RECRUITING

    Buenos Aires, 5044, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital San José

    NOT_YET_RECRUITING

    Hermosillo, Spain

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto Oriente Boliviano

    RECRUITING

    Santa Cruz de la Sierra, 10260, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.